International “No Smoking Day 2014” at Hadassah's Hospitals
In cooperation with the World Health Organization (WHO)’s “No Smoking Day 2014,” the Hadassah Medical Organization’s employees and visitors received up-to-date information about the negative health effects of smoking as well as advice on therapeutic interventions to help them delete this habit from their lives.
Hadassah was the first Israeli medical institution to ban smoking from its halls and its Center for Chronic Obstructive Pulmonary Disease (COPD) is the only holistic center in Israel that provides the most advanced multidisciplinary treatment for COPD patients.
The Institute of General Medicine comprises thirteen departments and nine Centers of Excellence. Each a leader in its field, the Centers include the Unit for the Early Detection of Colorectal Cancer, Center for Aging Research, National Center for Down Syndrome, and National SLE (LUPUS) Center. Its stellar Intensive Care Unit is world renowned.
Every patient is provided with an individualized treatment plan, which aims to enhance the person’s quality of life, through addressing physical, emotional, nutritional, and familial challenges that have resulted because of the smoking and subsequent COPD. The Center also helps patients stop smoking and deal with the withdrawal systems. As Center Founder Prof. Raphael Breuer explains: "We believe that the patient deserves not only lung medication, but also comprehensive care that addresses his needs in the community--whether it is planning a special diet to fight against obesity or underweight or granting emotional help.”
According to the WHO, six million people will die this year as a result of smoking-related health damage and a 10th of these will be due to second-hand smoke.
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>